COLL
Collegium Pharmaceutical, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +3 | 27.22M | $985.07M | +8 | −7 |
| Q1 2026 | 98 | -1 | 28.14M | $930.88M | +7 | −9 |
| Q4 2025 | 100 | 0 | 26.92M | $1.25B | +1 | n/a |
| Q3 2025 | 19 | +2 | 14.79M | $517.39M | +2 | n/a |
| Q2 2025 | 14 | +1 | 12.36M | $365.37M | +1 | n/a |
| Q1 2025 | 10 | -1 | 5.48M | $163.49M | n/a | −1 |
| Q4 2024 | 11 | -1 | 5.00M | $143.28M | n/a | −1 |
| Q3 2024 | 11 | -1 | 3.77M | $145.78M | n/a | −1 |
| Q2 2024 | 12 | n/a | 3.67M | $118.10M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 1.53M | n/a | $49.31M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 770.12K | n/a | $24.80M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 303.87K | n/a | $9.78M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 254.77K | n/a | $8.20M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 198.86K | n/a | $6.40M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 172.67K | n/a | $5.56M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 101.96K | n/a | $3.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 97.86K | n/a | $3.15M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Arrowstreet Capital ✦ | 72.74K | n/a | $2.34M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 70.96K | n/a | $2.29M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Gotham Asset Management ✦ | 61.42K | n/a | $1.98M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 30.86K | n/a | $994,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 264 holders, 37.57M shares, $1.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.